In a contradictory report, NRAS was found to be mutated in approximately 30% of AML patients with a biallelic mutation of CEPBA and 20% of cases with a NPM1 mutation [73,77,96,97]. This evidence concerns the gene NPM1 and acute myeloid leukemia.